var data={"title":"Sumatriptan: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sumatriptan: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7004?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sumatriptan-drug-information\" class=\"drug drug_general\">see &quot;Sumatriptan: Drug information&quot;</a> and <a href=\"topic.htm?path=sumatriptan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sumatriptan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224276\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alsuma [DSC];</li>\n      <li>Imitrex;</li>\n      <li>Imitrex STATdose Refill;</li>\n      <li>Imitrex STATdose System;</li>\n      <li>Onzetra Xsail;</li>\n      <li>Sumavel DosePro;</li>\n      <li>Zembrace SymTouch</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224277\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imitrex DF;</li>\n      <li>Imitrex Injection;</li>\n      <li>Imitrex Nasal Spray;</li>\n      <li>Sumatriptan DF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055584\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antimigraine Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055578\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sumatriptan-drug-information\" class=\"drug drug_general\">see &quot;Sumatriptan: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine: Note:</b> Results of clinical studies are mixed with regards to efficacy, particularly with oral and SubQ sumatriptan doses; a 2004 practice parameter concluded that sumatriptan nasal spray was effective for the acute treatment of migraines in adolescent patients (AAN [Lewis 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intranasal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 12 years: Limited data available: 5 mg, 10 mg, or 20 mg administered in one nostril <b>as a single dose</b> as soon as possible after the onset of migraine; dose should be selected on an individual basis. A double-blind, placebo controlled study of 129 patients (mean age: 12.4 years; range: 8 to 17 years) used a weight-based dosing regimen: Body weight: 20 to 39 kg: 10 mg/dose; body weight &ge;40 kg: 20 mg/dose; however, relatively few children &lt;12 years old were included in the study (Ahonen 2004). A small, randomized, double-blind, placebo-controlled study of 14 children (range: 6 to 9 years; median: 8.2 years) used intranasal doses of 20 mg/dose (Ueberall 1999). A small, retrospective review of 10 children (range: 5 to 12 years; mean: 9.9 years), used intranasal doses of 5 mg (n=2) or 20 mg (n=8) (Hershey 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents &le;17 years: Limited data available: 5 mg, 10 mg, or 20 mg administered in one nostril <b>as a single dose</b> as soon as possible after the onset of migraine; dose should be selected on an individual basis (AAN [Lewis 2004]; Rothner 2000; Winner 2000; Winner 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years and Adults: Initial single dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Powder: (Onzetra Xsail): 22 mg (11 mg nosepiece in each nostril). If headache has not resolved within 2 hours or returns, the dose may be repeated once &ge;2 hours after the first dose (maximum: 44 mg [4 nosepieces] per 24 hours or 22 mg [2 nosepieces] and one dose of another sumatriptan product [separated by &ge;2 hours] per 24 hours). The safety of treating an average of &gt;4 headaches in a 30-day period has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Solution: 5 mg, 10 mg, or 20 mg administered in one nostril as soon as possible after the onset of migraine; dose should be selected on an individual basis. A 10 mg dose may be achieved by administering as 5 mg in each nostril. If headache has not resolved within 2 hours or returns, the dose may be repeated once after 2 hours, not to exceed a total daily dose of 40 mg. In clinical trials, a greater number of patients responded to initial doses of 20 mg versus 5 or 10 mg. The safety of treating an average of &gt;4 headaches in a 30-day period has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &le;17 years: Limited data available; efficacy results variable; efficacy of oral sumatriptan was <b>not</b> established in five controlled trials in adolescent patients; frequency of adverse events was dose-related and age-dependent (ie, younger patients reported more adverse events)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years and Adults: Initial single dose: 25 mg, 50 mg, or 100 mg. If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials show that initial doses of 50 mg and 100 mg are more effective than doses of 25 mg, and that 100 mg doses do not provide a greater effect than 50 mg and may have increased incidence of side effects. Maximum daily dose (cumulative 24 hours): 200 mg total dose/24 hours. The safety of treating an average of &gt;4 headaches in a 30-day period have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>SubQ:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years and Adolescents &le;17 years: 3 to 6 mg single dose. An open-labeled prospective trial of 17 children 6 to 16 years with juvenile migraine used SubQ doses of 6 mg in 15 patients weighing 30 to 70 kg, and 3 mg/dose in two children weighing 22 kg and 30 kg (MacDonald 1994). Another open-label prospective trial in 50 consecutive children (ages 6 to 18 years) with severe migraine used SubQ doses of 0.06 mg/kg/dose. Relief was reported as good/excellent in 84% of the patients; 16% reported fair to poor relief; additional studies are needed (Linder 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Imitrex, Sumavel: Initial: 6 mg; if side effects are dose limiting, use lower doses: Imitrex: 1 to 5 mg or Sumavel: 4 mg. May repeat if needed &ge;1 hour after initial dose; maximum dose: 6 mg/dose; cumulative maximum 24-hour dose: 12 mg total dose (two 6 mg injections). Controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Zembrace: Initial: 3 mg; after 1 hour may repeat dose if needed up to 4 injections separated by at least 1 hour; may also administer following the dose of another sumatriptan product if separated by at least 1 hour; cumulative maximum 24-hour dose: 12 mg total dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, dosage adjustment not expected due to extensive metabolism to inactive agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate hepatic impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, because the intranasally administered drug does not undergo first-pass metabolism, serum concentrations would not be expected to be altered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: No dosage adjustment necessary; has been studied and pharmacokinetics were not altered in patients with hepatic impairment compared to healthy patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment: Oral, nasal, and SubQ (Imitrex and Zembrace injection) formulations are contraindicated with severe hepatic impairment. Sumavel is not recommended in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224252\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Exhaler Powder, Nasal, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onzetra Xsail: 11 mg per nosepiece (2 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose Refill: 4 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose System: 4 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alsuma: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose System: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose Refill: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Jet-injector, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sumavel DosePro: 4 mg/0.5 mL (0.5 mL [DSC]); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224238\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055588\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer as soon as symptoms appear.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder (Onzetra Xsail): For intranasal administration with the Xsail device only. Remove the clear device cap from the reusable delivery device; remove one 11 mg disposable nosepiece from the foil pouch and click into the device body. Prior to administration, pierce the capsule inside the nosepiece by pressing and releasing the white piercing button one time on the device body. Insert the nosepiece into one nostril so there is a tight seal; rotate the device to place the mouthpiece in the mouth. Blowing forcefully through the mouthpiece for 2 to 3 seconds will deliver the powder into the nasal cavity; vibration may occur. Do not press white button while blowing into mouthpiece. Once administered into the first nostril, remove and discard nosepiece; repeat same process using a second 11 mg nosepiece into the other nostril to administer the remainder of the 22 mg dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: Each nasal spray unit is preloaded with 1 dose; <b>do not</b> test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about <sup>1</sup>/<sub>2</sub> inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; <b>do not breathe deeply</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with water or other fluids; swallow tablet whole; do not split tablet</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer SubQ only; do <b>not</b> administer IM; do <b>not</b> administer IV (may cause coronary vasospasm). Needle penetrates <sup>1</sup>/<sub>4</sub> inch of skin; use in areas of the body with adequate skin and subcutaneous thickness (lateral thigh or upper arm). Do not use the auto-injector device for doses that are not 4 to 6 mg; vials should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Needleless administration (Sumavel DosePro): Do <b>not</b> administer IM; do <b>not</b> administer IV (may cause coronary vasospasm). Administer SubQ to the abdomen (&gt;2 inches from the navel) or thigh; do not administer to other areas of the body (eg, arm). Device is for single use only; discard after use; do not use if the tip of the device is tilted or broken; <b>Note:</b> A loud burst of air will be heard and a sensation in the skin will be felt at the time a dose is delivered with this device.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224273\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alsuma: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F); do not refrigerate. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imitrex injectable, tablet, intranasal: Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onzetra Xsail: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F); do not refrigerate or freeze. Use nosepiece immediately after removing from pouch (Onzetra Xsail).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sumavel DosePro, Zembrace: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F); do not freeze (Sumavel DosePro). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055587\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, intranasal, and tablets: Acute treatment of migraine with or without aura (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection (excluding Zembrace): Acute treatment of cluster headaches (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224330\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">SUMAtriptan may be confused with SAXagliptin, SITagliptin, somatropin, ZOLMitriptan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224328\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort, chest pressure, chest tightness, flushing, local discomfort (jaw or throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Burning sensation, dizziness, drowsiness, feeling hot, feeling of heaviness, headache, numbness, paresthesia, sedation, sensation of pressure, sensation of tightness, strange feeling, tight feeling in the head, tingling sensation, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction, warm sensation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia, neck pain, neck stiffness, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchospasm, nasal discomfort (nasal cavity), sinus discomfort</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Nasal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, localized burning, localized numbness, nasal cavity pain, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia, nausea, unusual taste, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local irritation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal discomfort, nasal signs and symptoms, rhinitis, rhinorrhea, sore nose, sinus discomfort</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Tablet:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, chest pressure, chest tightness, hot and cold flashes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue, feeling of heaviness, heaviness of chest, malaise, pain, paresthesia, sensation of pressure, sensation of tightness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Sore throat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Jaw pain, jaw pressure, jaw tightness, neck pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngeal edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Route unspecified:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Ischemia, Raynaud phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Splenic infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, angioedema, blindness, cerebral hemorrhage, cerebrovascular accident, dystonia, heaviness in neck (includes jaw or throat), hypersensitivity reaction, hypotension, myocardial infarction, neck pressure, neck tightness, seizure, subarachnoid hemorrhage, tremor, vision loss (partial)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224259\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, myocardial infarction, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT<sub>1</sub> agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment (excluding Sumavel)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224242\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/anaphylactoid reactions: Anaphylactic, anaphylactoid, and hypersensitivity reactions (including angioedema) have been reported; may be life threatening or fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration (some occurring within a few hours of administration). Discontinue sumatriptan if these events occur. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (may be fatal) have been reported with 5-HT<sub>1</sub> agonist administration. Discontinue sumatriptan if a cerebrovascular event occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. Use is contraindicated in patients with uncontrolled hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Transient and permanent blindness and significant partial vision loss have been reported (rare) with use of 5-HT<sub>1</sub> agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome may occur with 5-HT<sub>1</sub> agonists, particularly when used concomitantly with other serotonergic drugs; symptoms (eg, diarrhea, hyperreflexia, hyperthermia, incoordination, mental status changes, nausea, tachycardia, vomiting) typically occur minutes to hours after initiation/dose increase of a serotonergic drug. Discontinue use if serotonin syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasospasm-related events: Peripheral vascular ischemia, GI vascular ischemia and infarction, splenic infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery disease: Perform a cardiovascular evaluation in 5-HT<sub>1</sub> agonists-naive patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) prior to initiation of therapy. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the health care provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in these patients during intermittent long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use oral formulations of sumatriptan with caution (and with dosage limitations) in patients with mild to moderate hepatic impairment where treatment is necessary and advisable. Presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations; dosage reduction of the oral product is recommended. Non-oral routes of administration (intranasal, subcutaneous) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, intranasal, Alsuma, Imitrex, and Zembrace injectable is contraindicated in severe hepatic impairment; Sumavel is not recommended in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with history of seizure disorder or in patients with a lowered seizure threshold; seizures have been reported after sumatriptan administration in patients with or without a history of seizures.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; perform a cardiovascular evaluation prior to initiation of therapy in elderly patients with cardiovascular risk factors (eg, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) and periodically during intermittent long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine or cluster headache prophylaxis, or for the treatment of hemiplegic or basilar migraine. Acute migraine agents (eg, 5-HT<sub>1</sub> agonists, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine or cluster headache should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine or cluster headache.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25956060\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;\">Serious adverse effects, such as MI, stroke, visual loss, and death, have been reported in pediatric patients after sumatriptan use by the oral, intranasal, and/or SubQ routes; frequency of such adverse effects cannot currently be determined, monitor patients closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300101\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224247\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12821&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin 5-HT1D Receptor Agonists: May enhance the adverse/toxic effect of SUMAtriptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224249\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224262\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In a study using full-term, healthy human placentas, limited amounts of sumatriptan were found to cross the placenta (Schenker 1995).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy outcome information for sumatriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 617 pregnancies (626 infants/fetuses) exposed to sumatriptan (including 7 pregnancies also exposed to naratriptan). Following sumatriptan exposure, the risk of major birth defects following first trimester exposure was 4.2% and no consistent pattern of birth defects was observed. The pregnancy registry was closed to enrollment in January 2012 (Ephross 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not observed following sumatriptan exposure (2,229 exposed during the first trimester) (K&auml;ll&eacute;n 2011). An increased risk of major congenital malformations was also not observed using data collected from a Norwegian pregnancy registry study. This study included 415 women who used sumatriptan during the first trimester of pregnancy between 2004 and 2007 (Nezvalov&aacute;-Henriksen 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If treatment for cluster headaches is needed during pregnancy, sumatriptan may be used (J&uuml;rgens 2009). Other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva 2012; MacGregor 2014; Williams 2012); however, sumatriptan may be considered if first-line agents fail (MacGregor 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224241\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) on intracranial blood vessels and sensory nerves of the trigeminal system; causes vasoconstriction and reduces neurogenic inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224258\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: ~30 minutes; Intranasal: Solution: ~15 to 30 minutes; SubQ: ~10 minutes; Peak effect: Oral: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> (central): SubQ: 50 L; V<sub>d</sub> (apparent): Oral, Intranasal powder and solution: 2.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 14% to 21%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to an indole acetic acid metabolite (inactive) which then undergoes ester glucuronide conjugation; may be metabolized by monoamine oxidase (MAO); extensive first-pass metabolism following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: Solution 17%, Powder 19% (compared to SubQ); Oral: 15%; SubQ: 97% &plusmn; 16%; <b> Note</b>: Sumavel DosePro is bioequivalent to sumatriptan SubQ injection via needle when administered into the thigh or abdomen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Distribution: 15 minutes; Terminal: 2 hours; range: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 2 to 2.5 hours; Intranasal: Powder: ~45 minutes; SubQ: 12 minutes (range: 4 to 20 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Urine (42% of total dose as indole acetic acid metabolite; 3% of total dose as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Urine (~60% of total dose, mostly as indole acetic acid metabolite; 3% of total dose as unchanged drug); feces (~40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Urine (38% of total dose as indole acetic acid metabolite; 22% of total dose as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11450256\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 5 mg/mL oral liquid preparation made from tablets and one of three different vehicles (Ora-Sweet&reg;, Ora-Sweet&reg; SF, or Syrpalta&reg; syrups). <b>Note:</b> Ora-Plus&reg; Suspending Vehicle is used with Ora-Sweet&reg; or Ora-Sweet&reg; SF to facilitate dispersion of the tablets (Ora-Plus&reg; is not necessary if Syrpalta&reg; is the vehicle). Crush nine 100 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of Ora-Plus&reg; in 5 mL increments and mix thoroughly between each addition; rinse mortar and pestle 5 times with 10 mL of Ora-Plus&reg;, pouring into bottle each time, and add quantity of appropriate syrup (Ora-Sweet&reg; or Ora-Sweet&reg; SF) sufficient to make 180 mL. Store in amber glass bottles in the dark; label &quot;shake well&quot;, &quot;refrigerate&quot;, and &quot;protect from light&quot;. Stable for 21 days refrigerated.</p>\n    <div class=\"reference\">Fish DN, Beall HD, Goodwin SD, et al, &quot;Stability of Sumatriptan Succinate in Extemporaneously Prepared Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(14):1619-22.<span class=\"pubmed-id\">9248606</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224261\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exhaler Powder</b> (Onzetra Xsail Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11MG/NOSEPC (2): $103.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Imitrex Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (1): $94.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/ACT (1): $94.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Imitrex Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $221.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SUMAtriptan Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (1): $61.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/ACT (1): $61.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SUMAtriptan Succinate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Imitrex STATdose System Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $237.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $237.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (SUMAtriptan Succinate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $107.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $187.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Zembrace SymTouch Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/0.5 mL (0.5 mL): $188.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Imitrex STATdose Refill Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $225.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $225.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imitrex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (9): $314.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (9): $684.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (9): $684.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SUMAtriptan Succinate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (9): $243.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (9): $226.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (9): $226.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224264\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adracon (PE);</li>\n      <li>Apigrane (JO);</li>\n      <li>Cetatrex (ID);</li>\n      <li>Cinie (LV);</li>\n      <li>Fermig (MX);</li>\n      <li>Imigran (AE, AT, AU, BB, BG, BH, BM, BR, BS, BZ, CH, CL, CY, CZ, DE, DK, EC, EE, EG, ES, FI, GB, GR, GY, HK, HN, HR, HU, IE, IS, IT, JM, JO, KR, KW, LB, LK, LT, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SR, TH, TR, TT, TW, UY, VE, VN, ZW);</li>\n      <li>Imigran FDT (SG);</li>\n      <li>Imigran Nasal Spray (QA, SA);</li>\n      <li>Imigran Radis (GB);</li>\n      <li>Imigrane (FR);</li>\n      <li>Imihran (UA);</li>\n      <li>Imiject (FR);</li>\n      <li>Imitrex (BE, IL, LU);</li>\n      <li>Micranil (AR);</li>\n      <li>Migane (ET);</li>\n      <li>Migraban (QA);</li>\n      <li>Migragesin (CO);</li>\n      <li>Migraval (VE);</li>\n      <li>Na Chuan (CN);</li>\n      <li>Nograine (MX);</li>\n      <li>Nomigra (BD);</li>\n      <li>Rontadol (AR);</li>\n      <li>Sitran (CO);</li>\n      <li>Somatran (CL);</li>\n      <li>Sumagran (AU);</li>\n      <li>Sumalux (BD);</li>\n      <li>Sumamihren (UA);</li>\n      <li>Sumatab (AU);</li>\n      <li>Sumatan (BD);</li>\n      <li>Sumatran (IE, SG);</li>\n      <li>Sumatridex (IL);</li>\n      <li>Sumavel DosePro (DE, DK);</li>\n      <li>Sumax (BR);</li>\n      <li>Sumig (PH);</li>\n      <li>Sumitran (MY, SG);</li>\n      <li>Sumitrex (IN, MX);</li>\n      <li>Sutagran (VN);</li>\n      <li>Tebegran (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahonen K, H&auml;m&auml;l&auml;inen ML, Rantala H, et al, &quot;Nasal Sumatriptan Is Effective in Treatment of Migraine Attacks in Children: A Randomized Trial,&quot; <i>Neurology</i>, 2004, 62(6):883-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15037686/pubmed\" target=\"_blank\" id=\"15037686\">15037686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunnington M, Ephross S, and Churchill P, &quot;The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?&quot; <i>Headache</i>, 2009, 49(10):1414-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19804390/pubmed\" target=\"_blank\" id=\"19804390\">19804390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Da Silva AN and Tepper SJ, &quot;Acute Treatment of Migraines,&quot; <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22823482/pubmed\" target=\"_blank\" id=\"22823482\">22823482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. <i>Headache</i>. 2014;54(7):1158-1172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24805878/pubmed\" target=\"_blank\" id=\"24805878\">24805878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert: MedWatch. FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch. Available at: <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm</a>. Accessed June 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gunner KB, Smith HD, and Ferguson LE, &quot;Practice Guideline for Diagnosis and Management of Migraine Headaches in Children and Adolescents: Part Two,&quot; <i>J Pediatr Health Care</i>, 2008, 22(1):52-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/18174091/pubmed\" target=\"_blank\" id=\"18174091\">18174091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershey AD, Powers SW, LeCates S, et al, &ldquo;Effectiveness of Nasal Sumatriptan in 5- to 12-Year-Old Children,&rdquo; <i>Headache</i>, 2001, 41(7):693-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11554957 /pubmed\" target=\"_blank\" id=\"11554957 \">11554957 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imitrex injection (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imitrex tablets (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&uuml;rgens TP, Schaefer C, and May A, &quot;Treatment of cluster headache in pregnancy and lactation,&quot; Cephalalgia. 2009 Apr;29(4):391-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/19170693/pubmed\" target=\"_blank\" id=\"19170693\">19170693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, &quot;Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden,&quot; <i>Drug Saf</i>, 2011, 34(8):691-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/21751829/pubmed\" target=\"_blank\" id=\"21751829\">21751829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis D, Ashwal S, Hershey A, et al, &quot;Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2004, 63(12):2215-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/15623677/pubmed\" target=\"_blank\" id=\"15623677\">15623677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linder SL, &quot;Subcutaneous Sumatriptan in the Clinical Setting: The First 50 Consecutive Patients With Acute Migraine in a Pediatric Neurology Office Practice,&quot; <i>Headache</i>, 1996, 36(7):419-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8783473/pubmed\" target=\"_blank\" id=\"8783473\">8783473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDonald JT, &ldquo;Treatment of Juvenile Migraine With Subcutaneous Sumatriptan,&rdquo; <i>Headache</i>, 1994, 34(10):581-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/7843952 /pubmed\" target=\"_blank\" id=\"7843952 \">7843952 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor EA, &quot;Headache in Pregnancy,&quot; <i>Neurol Clin</i>, 2012, 30(3):835-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22840792/pubmed\" target=\"_blank\" id=\"22840792\">22840792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor EA. Migraine in pregnancy and lactation. <i>Neurol Sci</i>. 2014;35(Suppl 1):61-64. doi: 10.1007/s10072-014-1744-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/24867839/pubmed\" target=\"_blank\" id=\"24867839\">24867839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng HM, &quot;Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Sohort Study,'&quot; <i>Headache</i>, 2012, 52(8):1319-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22946832/pubmed\" target=\"_blank\" id=\"22946832\">22946832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nezvalov&aacute;-Henriksen K, Spigset O, and Nordeng H, &quot;Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,&quot; <i>Headache</i>, 2010, 50(4):563-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/20132339/pubmed\" target=\"_blank\" id=\"20132339\">20132339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23884894\"></a>Nezvalov&aacute;-Henriksen K, Spigset O, Nordeng H, et al. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769. doi: 10.1007/s10654-013-9831-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/23884894/pubmed\" target=\"_blank\" id=\"23884894\">23884894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onzetra Xsail (sumatriptan nasal powder) [prescribing information]. Aliso Viejo, CA: Avanir Pharmaceuticals; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rothner AD, Winner P, Nett R, et al, &quot;One-Year Tolerability and Efficacy of Sumatriptan Nasal Spray in Adolescents With Migraine: Results of a Multicenter, Open-Label Study,&quot; <i>Clin Ther</i>, 2000, 22(12):1533-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11192144/pubmed\" target=\"_blank\" id=\"11192144\">11192144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker S, Yang Y, Perez A, et al, &quot;Sumatriptan (Imitrex) Transport by the Human Placenta,&quot; <i>Proc Soc Exp Biol Med</i>, 1995, 210(3):213-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8539258/pubmed\" target=\"_blank\" id=\"8539258\">8539258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott AK, &ldquo;Sumatriptan Clinical Pharmacokinetics,&rdquo; <i>Clin Pharmacokinet</i>, 1994, 27(5):337-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/ 7851052 /pubmed\" target=\"_blank\" id=\" 7851052 \"> 7851052 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silver S, Gano D, and Gerretsen P, &quot;Acute Treatment of Paediatric Migraine: A Meta-analysis of Efficacy,&quot; <i>J Paediatr Child Health</i>, 2008, 44(1-2):3-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/17854415/pubmed\" target=\"_blank\" id=\"17854415\">17854415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sumavel DosePro (sumatriptan) [prescribing information]. San Diego, CA: Zoginex Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ueberall MA and Wenzel D, &quot;Intranasal Sumatriptan for the Acute Treatment of Migraine in Children,&quot; <i>Neurology</i>, 1999, 52(7):1507-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/10227648/pubmed\" target=\"_blank\" id=\"10227648\">10227648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SH and Kehr HA, &quot;An Update in the Treatment of Neurologic Disorders During Pregnancy-Focus on Migraines and Seizures,&quot; <i>J Pharm Pract</i>, 2012, 25(3):341-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/22550159/pubmed\" target=\"_blank\" id=\"22550159\">22550159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winner P, Rothner AD, Saper J, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents,&rdquo; <i>Pediatrics</i>, 2000, 106(5):989-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/11061765/pubmed\" target=\"_blank\" id=\"11061765\">11061765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winner P, Rothner AD, Wooten JD, et al, &quot;Sumatriptan Nasal Spray in Adolescent Migraineurs: A Randomized, Double-Blind, Placebo-Controlled, Acute Study,&quot; <i>Headache</i>, 2006, 46(2):212-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wojnar-Horton RE, Hackett LP, Yapp P, et al, &quot;Distribution and Excretion of Sumatriptan in Human Milk,&quot; <i>Br J Clin Pharmacol</i>, 1996, 41(3):217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-pediatric-drug-information/abstract-text/8866921/pubmed\" target=\"_blank\" id=\"8866921\">8866921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zembrace SymTouch (sumatriptan succinate) [prescribing information]. San Diego, CA: Dr. Reddy&rsquo;s; March 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12821 Version 198.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224276\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F224277\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055584\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055578\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224252\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F224238\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055588\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F224273\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055587\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F224330\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224328\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224259\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224242\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25956060\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300101\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F224247\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F224249\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224262\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224241\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F224258\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11450256\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F224261\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224264\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12821|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sumatriptan-drug-information\" class=\"drug drug_general\">Sumatriptan: Drug information</a></li><li><a href=\"topic.htm?path=sumatriptan-patient-drug-information\" class=\"drug drug_patient\">Sumatriptan: Patient drug information</a></li></ul></div></div>","javascript":null}